Laura Mezquita on Lung Cancer Prevention Strategies Ahead of ESMO 2026
As ESMO 2026 approaches, Laura Mezquita discusses her focus on lung cancer prevention and the importance of integrating environmental factors into patient care.
Lung cancer remains the leading cause of cancer mortality globally, with significant research advancements in its prevention.
Mezquita emphasizes the need for improved education among oncologists regarding cancer prevention and early detection.
Upcoming ESMO Congress will showcase new data on treatment options for small-cell lung cancer, potentially changing clinical practices.
Laura Mezquita, a prominent figure in thoracic oncology, is gearing up for the upcoming ESMO 2026 Congress, where she will share insights on lung cancer prevention. With lung cancer being the most prevalent thoracic tumor and a leading cause of cancer-related deaths worldwide, Mezquita highlights the critical importance of understanding environmental factors that contribute to the disease. Her research has evolved from a personal experience with a young patient, leading her to focus on radon exposure and its implications for lung cancer in non-smokers.
Mezquita's work diverges from traditional thoracic oncology by concentrating on prevention strategies rather than solely treatment. As the newly appointed Chair of the European Society of Medical Oncology's Cancer Prevention and Interception Committee, she aims to enhance education for oncologists about cancer prevention. She stresses that while oncologists are well-trained in diagnosis and treatment, there is a significant gap in their education regarding preventive measures. Strengthening collaboration between oncologists and epidemiologists is also a priority for her, as it can lead to better risk assessment and early detection strategies.
In her role, Mezquita is focused on developing practical tools to gather comprehensive patient histories that include not just smoking but also environmental and occupational exposures. She believes that integrating these factors into routine clinical care can significantly improve cancer prevention efforts. Additionally, she advocates for public health measures and tobacco control policies, emphasizing that cancer prevention should be a shared responsibility among all cancer specialists.
As the ESMO Congress in Madrid approaches, Mezquita anticipates the presentation of groundbreaking data, particularly concerning small-cell lung cancer. This subtype, although less common, poses significant treatment challenges and has a poor prognosis. New treatment options could potentially revolutionize care for these patients. Furthermore, she highlights the need for advancements in predicting responses to immunotherapy, as current biomarkers like PD-L1 are insufficient for identifying all patients who will benefit from treatment.
Looking ahead, Mezquita envisions a future where lung cancer screening and prevention are more accessible and effective. She calls for initiatives to enhance awareness of various risk factors beyond smoking, such as vaping and radon exposure. Improving the quality of screening programs and identifying high-risk populations are crucial steps she hopes to see achieved in the next five years, aiming for earlier detection and increased chances of successful treatment.




